Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Oral tazarotene delivers lasting results
Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
